Study Summaries

In low-grade serous ovarian cancer, Binimetinib did not significantly improve PFS compared to standard of care chemotherapy.

Surgery did not improve overall survival, but it showed a benefit in certain analyses. This supports the potential efficacy of secondary cytoreduction in specialized centers and for selected patients.

Adding bevacizumab to chemotherapy significantly improves PFS and ORR in patients with platinum-resistant recurrent ovarian cancer.

- Adding bevacizumab to gemcitabine and carboplatin significantly improves PFS but no difference in OS in platinum-sensitive recurrence

Continuing bevacizumab beyond progression combined with chemotherapy significantly improves progression-free survival in patients with platinum-sensitive recurrent ovarian cancer compared to standard chemotherapy alone, but no OS benefit

The addition of bevacizumab to standard chemotherapy (paclitaxel and carboplatin) improves PFS significantly and may offer a clinically meaningful improvement in OS.

Maintenance olaparib provides a clinically meaningful improvement in OS for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. The 7-year follow-up data support its use for long-term remission.

Docetaxel-carboplatin is similar to paclitaxel-carboplatin in terms of progression-free survival and overall response but has significantly less neurotoxicity. It represents an alternative first-line chemotherapy regimen for patients with newly diagnosed ovarian cancer.